Načítá se...

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gas...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Koizumi, W, Tanabe, S, Saigenji, K, Ohtsu, A, Boku, N, Nagashima, F, Shirao, K, Matsumura, Y, Gotoh, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2003
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2395274/
https://ncbi.nlm.nih.gov/pubmed/14676796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601413
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!